ISSCA Announces New Buenos Aires Symposium
The International Society of Stem Cell Applications (ISSCA) has hereby announced the date of it’s seventh Symposium of Regenerative Medicine. As before, the organization hopes to bring together a network of regenerative medicine practitioners from all over the world to foster a growth of knowledge among them. It will go over a wide range of topics related to regenerative medicine, chiefly among them will be the response of all levels of regenerative medicine research and practice in the COVID-19 pandemic, as well as what the future looks like for the field as a result of it. In addition to this, the symposium will also cover breakthroughs in the field, new treatment options and technological developments that are now available to both doctors and patients.
Cellular Therapies During and After the Pandemic
Cellular therapies have been an invaluable asset in managing the largest pandemic in modern history. This has been evidenced by the use of Mesenchymal cells, along with other growth factors and types of cells, to treat respiratory failure and manage some of the complications induced by exposure to COVID-19. This has resulted in accelerated pathways for regulatory approval and increased funding for new regenerative medicine-based clinical trials.
We are living in a unique time for regenerative medicine, as advancements are being made month after month, year after year at a rapid, exponential rate. Keeping track of the latest advancements in this research and development, and the medical protocols that occur as a result, is critical to safeguarding lives all over the world. Every medical society’s purpose is, primarily, to promote the growth of both their members and the field that they operate in. The International Society for Stem Cell Applications (ISSCA), strives to do just that. In the interest of designing the future of cellular therapies in a post-pandemic world, ISSCA invites pioneers of the field from around the world to form and share in a platform of experiences, knowledge, and progress.
Stem Cells Group to Host Regenerative Medicine Symposium in Buenos Aires, Argentina November 28th
After a period of silence brought about by the global COVID-19 pandemic, the Global Stem Cells Group (GSCG) is prepared to begin bringing medical professionals together by hosting a Regenerative Medicine Symposium in Buenos Aires, Argentina. The Symposium will take place at the Hotel Panamericano, Buenos Aires, on the 28th of November.
The Buenos Aires symposium will feature a wide variety of educational resources, including lectures and demonstrations, as well as product information. All of this is aimed at doctors that are looking to incorporate regenerative medicine into their practices. Industry experts will be on hand to impart the latest information on the newest compounds in the allogeneic stem cell market, including exosomes, amniotic fluid compounds, and umbilical cord blood products. Allogeneic compounds have steadily been increasing in popularity within the field of regenerative medicine, and this is due to their increased safety and treatment efficacy as research has evolved. With this in mind, GSCG representatives will be on hand to give physicians the opportunity to learn more about these popular treatment solutions and how they can be utilized in their own practices.
ISSCA CEO Benito Novas had this to say about the upcoming event: “We’ve barely even scratched the surface of potential for regenerative medicine, which is why it’s so important that we collectively gather and learn about what we’ve done thus far. This is a South
American congress that will witness some of the greatest regenerative doctors of our time
giving once-in-a-lifetime addresses to those in attendance.”
Among these speakers are Drs. Damian Siano, Silvina Pastrana, and Maritza Novas. Dr. Siano will look specifically at sports injuries, and draw on his experience as a sports medicine specialist aiding professional athletes in the world today. Dr. Pastrana, the Medical Director of the Buenos Aires Stem Cells Center, will speak about how stem cells can help to assuage aesthetic conditions. Dr. Novas, an ISSCA Fellow in Cell Therapy and Tissue Engineering, will look at the fundamentals of stem cell biology and their clinical applications. She will cover a broad range of topics concerning MSCs during their transition from bench-side to bedside.
In addition to the wide array of educational sessions offered, the Buenos Aires symposium will also provide a wide array networking and social opportunities for those physicians in attendance. To learn more about ISSCA’s upcoming Buenos Aires Symposium, or to register for the event, visit us at: https://www.issca.us/
About ISSCA
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com
- Published in News
ISSCA Announces its 2020 Schedule of Regenerative Medicine Congresses
The group will host six events across the globe, combining networking and education for practitioners of regenerative medicine
MIAMI LAKES, Florida— The International Society for Stem Cell Application (ISSCA), a worldwide leader in regenerative medicine education, has announced its slate of 2020 medical congresses. The group’s calendar includes dates at six locations across the globe
Through its congresses, the ISSCA seeks to create a platform through which physicians can collaborate, share data, initiate discussions, and exchange information that may be directly translated to therapeutic applications. All doctors who want to share their medical research are welcome to attend, and the ISSCA welcomes abstract submissions and reviews them on a continuing basis.
For the second year straight, the main topic discussed at ISSCA’s congresses will be how cellular products derived from birth tissue (allogeneic compounds) have revolutionized the industry by delivering safer, shorter stem cells procedures for practitioners. During each event, lecturers will respond to concerns attendees have about how regenerative medicine advances will satisfy FDA regulations and how new technologies could continue to help patients under new FDA laws.
This year, the ISSCA welcomes three new cities to its agenda—Salvador de Bahia, Brazil; Punta del Este, Uruguay; and Jakarta, Indonesia. The six congresses are as follows:
- May 2020: Mexico City, Mexico
- June 2020: Caracas, Venezuela
- August 2020: Salvador de Bahia, Brazil
- October 2020: Buenos Aires, Argentina
- November 2020: Jakarta, Indonesia
- December 2020: Punta del Este, Uruguay
“We at the ISSCA are looking forward to this year’s calendar of congresses, which will provide invaluable networking and educational opportunities to physicians looking to expand their knowledge on current innovations and best practices concerning regenerative medicine,” noted Benito Novas, ISSCA VP of Public Relations. “Our global congresses expand on ISSCA’s mission to continue to serve as the premier educational resource for physicians across the globe looking to introduce stem cells treatments into their practices.”
To learn more about the ISSCA or to register for an upcoming congress, visit www.issca.us.
- Published in News
Global Stem Cells Group Releases New Product to Meet Growing Demand for Birth Tissue Derived Compounds
Cellgenic Flow Exosomes has a wide range of therapeutic implications, including hair loss and pain management
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) has announced the release of a new product in response to growing demands from regenerative medicine practitioners for cellular products derived from birth tissue. The product, Cellgenic Flow Exosomes, is 100% natural and is available in a 1 mL vial comprised of 5 billion exosomes per mL and is currently manufactured in Mexico and in Global’s US-based facilities.
As the popularity and efficacy of stem cells treatments increase across the globe, the demand for cellular products like Cellgenic have also increased. With this demand in mind, the GSCG–a global leader in stem cell research, patient application, and physician training–sought to create an innovative cellular product to meet the needs of physicians looking to offer regenerative medicine treatments in their existing practices.
Cellgenic is primarily comprised of exosomes, cell-derived non-particles that play a pivotal role in cell-to-cell communication that are involved in a wide range of physiological processes. Exosomes play an important role in the transfer of proteins, mRNA, miRNA, and other bioactive molecules between cells and regulate gene expression in recipient cells, thus influencing various molecular pathways.
An increasing amount of attention has been paid to exosomes in recent years thanks to the wide range of therapeutic implications they may hold. Some of the most effective uses for exosomes have come in hair therapy and pain management.
Using Cellgenic as a treatment for hair loss has resulted in prominent hair growth results in both men and women. It is highly recommended for those who are too young for hair transplant surgery and for those within the earlier stages of the hair loss cycle.
In terms of pain management, Cellgenic has shown promise in delivering relief from pain and discomfort and may potentially stimulate repair as opposed to blocking or masking them. Common pain and degenerative conditions that Cellgenic may help treat include osteoarthritis, knee pain, shoulder pain, nerve pain, tendonitis, and slow- and non-healing wounds and burns.
For doctors who are interested in learning more about Cellgenic, the GSCG has developed an online course to provide them with the relevant knowledge needed to make a decision about incorporating allogeneic compounds into their treatment protocols.
“Global’s newest product innovation, Cellgenic Flow Exosomes, is an exciting addition to our product portfolio,” said Benito Novas, CEO of the Global Stem Cells Group. “Our goal is to continually innovate and meet the demands of physicians practicing regenerative medicine by providing cutting-edge therapies for those suffering from degenerative diseases. The release of our Cellgenic product accomplishes this goal while also contributing to our mission of being a leader in stem cells research.”
To learn more about Cellgenic Flow Exosomes, visit https://cellgenic.com/.
- Published in News
Knee replacement alternatives
Knee replacement, also known as knee arthroplasty, involves replacing a knee joint with a prosthetic device. Explore the alternatives to this procedure and their benefits.
Why Consider Knee Replacement Alternatives?
Many patients seek alternatives due to persistent pain and potential risks associated with knee replacement surgery.
Challenges of Knee Replacement
Patients often experience continued pain post-surgery, with studies showing significant discomfort even years later.
Common Risks of Knee Replacement
Understand the risks involved, including increased susceptibility to cardiovascular events and allergic reactions to prosthetic materials.
Types of Knee Replacement Alternatives
Discover effective alternatives that offer relief without the complexities of surgery.
Steroid Injections
While providing short-term relief, steroid injections may not offer long-term solutions due to their impact on cartilage.
Viscosupplementation
Gel-like substances such as hyaluronic acid injections offer relief for knee arthritis, though effectiveness may vary over multiple doses.
Knee Nerve Ablation
A promising procedure that involves disabling nerves around the knee joint to alleviate pain, though long-term outcomes are still under study.
Orthobiologics
Utilizing natural substances like PRP and BMC to promote healing and reduce degradation of knee tissues, offering both autologous and allogeneic options.
Platelet Rich Plasma (PRP)
Derived from the patient’s blood, PRP injections foster cartilage repair and reduce inflammation, beneficial for moderate knee arthritis.
Percutaneous Knee Arthroplasty (PKA)
A sophisticated procedure involving precise injections of bone marrow concentrates guided by ultrasound, effective even in severe cases of knee arthritis.
- Published in Blog
ISSCA Offers New Online Cellular Therapy Course
With video lectures and additional tools from some of the most respected names in today’s stem cells field, the course arms practitioners with the necessary knowledge and resources to offer innovative regenerative medicine treatments in their existing practices
MIAMI LAKES, Florida— The International Society for Stem Cell Application (ISSCA) (www.issca.us) has announced it has launched a new online stem cells course, Cellular Therapy. The course adds to the group’s already existing robust offering of onsite and online courses designed to give physicians looking to incorporate regenerative medicine protocols into their practices the education and tools necessary to do so.
Regenerative medicine has been increasingly gaining attention in today’s fast-paced medical world. As more researchers and physicians become interested in studying the field and introducing treatment protocols into their practices, it can be difficult to know which products and practices yield the best results for patients seeking these treatments for relief from degenerative diseases, noted Benito Novas, ISSCA VP of Public Relations. Knowing which products work for which conditions and how to safely administer them to maximize results are key in leading a successful regenerative medicine practice.
With the Cellular Therapy course and others offered by the ISSCA, physicians will learn these valuable protocols and more about product offerings and how to choose the most effective ones. The Cellular Therapy course will prepare physicians with the necessary theoretical and practical knowledge needed to effectively and safely secure better patient outcomes when using cellular therapies. With this training, physicians will gain knowledge from leading scientists in the field, learn valuable information on safety standards and quality control from top manufacturers, be positioned to perform these procedures and open a Stem Cell Center practice, join the ISSCA’s network, and enjoy the benefits of an exponentially growing industry worldwide.
Practitioners enrolling in the online course will gain access to online lectures from some of the leading names in the field of regenerative medicine spanning a number of topics critical to understanding the foundations of cellular therapy. In addition to online lectures, enrollees gain access to important supporting documents; The Condition Book, outlining stem cells treatment protocols for seven common conditions; and valuable case studies, all designed to deliver the knowledge needed to successfully implement stem cells treatments in a clinical setting.
And physicians looking to enroll in this course and other offerings by the ISSCA are in good hands. The group is widely considered as the global standard bearer when it comes to education and research in the regenerative medicine field. For years, the ISSCA has played a critical role in bridging the gap between the science behind stem cells and regenerative medicine and the practical application of that science in a clinical setting.
“We are pleased to add the online Cellular Therapy course to our growing number of course offerings designed to deliver the skills and education needed to practitioners eager to implement stem cells treatment protocols into their existing practices,” said Novas. “The course gives physicians the skills needed to utilize these highly effective treatments to help patients suffering from degenerative diseases while expanding on the ISSCA’s mission to continue to serve as the premier educational resource for physicians across the globe looking to introduce stem cells treatments into their practices.”
To learn more about the ISSCA, visit www.issca.us. To learn more about the group’s new online Cellular Therapy course or to register, visit https://www.cellulartherapycourse.com/
- Published in News